2015
-
Selt F, Deiß A, Korshunov A, Capper D, Witt H, van Tilburg CM, Jones DT, Witt R, Sahm F, Reuss D, Kölsche C, Ecker J, Oehme I, Hielscher T, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T. Pediatric targeted therapy: Clinical feasibility of personalized diagnostics in children with relapsed and progressive tumors. Brain Pathol. 2015 Oct 7.
-
2. Tallen G, Resch A, Calaminus G, Wiener A, Leiss U, Pletschko T, Friedrich C, Langer T, Grabow D, Driever PH, Kortmann RD, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Thomale UW, Krauss J, Mynarek M, von Hoff K, Ottensmeier H, Frühwald M, Kramm CM, Temming P, Müller HL, Witt O, Kordes U, Fleischhack G, Gnekow A, Rutkowski S; German Paediatric Brain Tumour Consortium (HIT-Network). Strategies to improve the quality of survival for childhood brain tumour survivors. Eur J Paediatr Neurol. 2015 Nov;19(6):619-39.
-
3. Rieber JG, Kessel KA, Witt O, Behnisch W, Kulozik AE, Debus J, Combs SE. Treatment tolerance of particle therapy in pediatric patients. Acta Oncol. 2015 Jul;54(7):1049-55.
-
4. Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol Sci. 2015 Jul;36(7):481-92.
-
5. Ecker J, Oehme I, Mazitschek R, Korshunov A, Kool M, Hielscher T, Kiss J, Selt F, Konrad C, Lodrini M, Deubzer HE, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun. 2015 Apr 3;3:22.
-
6. Koeneke E, Witt O, Oehme I. HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities. Cells. 2015 Apr 23;4(2):135-68.
-
7. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol. 2015 May;129(5):669-78.
-
8. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M, Pfister SM. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015 May 11;27(5):728-43.
-
9. Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, Fabian J, Schober A, Fernekorn U, von Deimling A, Deubzer HE, Milde T, Witt O, Oehme I. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis. 2015 Feb 19;6:e1657.
2014
-
1. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R6, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014 Dec;15(13):1513-20.
-
2. Liu L, Detering JC, Milde T, Haefeli WE, Witt O, Burhenne J. Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood, J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Aug 1;964:212-21. doi: 10.1016/j.jchromb.2014.02.014. Epub 2014 Feb 18. PMID: 24636840 [PubMed - in process]
-
3. Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S29, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014 Jul 24;511(7510):428-34.
-
4. Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber UD, Bartholomae CC, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor MD, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya RJ, Eils R, Yaspo ML, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing, Nature. 2014 Jun m26;510(7506):537-41. doi: 10.1038/nature13268. Epub 2014 May 18. PMID: 24847876 [PubMed - indexed for MEDLINE]
-
5. Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM; ICGC PedBrain Tumor Project. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition, Cancer Cell. 2014 Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004. PMID: 24651015 [PubMed - indexed for MEDLINE]
-
6. Benesch M, Bartelheim K, Fleischhack G, Gruhn B, Schlegel PG, Witt O, Stachel KD, Hauch H, Urban C, Quehenberger F, Massimino M, Pietsch T, Hasselblatt M, Giangaspero F, Kordes U, Schneppenheim R, Hauser P, Klingebiel T, Frühwald MC. High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplant. 2014 Mar;49(3):370-5.
-
7. Mack C, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis T, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, Agnihotri S, Cavalli FM, Clarke I, Nethery-Brokx K, Creasy CL, Verma SK, Koster J, Wu X, Yao Y, Milde T, Sin-Chan P, Zuccaro J, Lau L, Pereira S, Castelo-Branco P, Hirst M, Marra MA, Roberts SS, Fults D, Massimi L, Cho YJ, Van Meter T, Grajkowska W, Lach B, Kulozik AE, von Deimling A, Witt O, Scherer SW, Fan X, Muraszko KM, Kool M, Pomeroy SL, Gupta N, Phillips J, Huang A, Tabori U, Hawkins C, Malkin D, Kongkham PN, Weiss WA, Jabado N, Rutka JT, Bouffet E, Korbel JO, Lupien M, Aldape KD, Bader GD, Eils R, Lichter P, Dirks PB, Pfister SM, Korshunov A, Taylor MD. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy, Nature. 2014 Feb 27;506(7489):445-50. doi: 10.1038/nature13108. Epub 2014 Feb 19.
-
8. Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S, Hielscher T, Pfister SM, Witt O, Rommelaere J, Schlehofer JR, Witt H. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer. 2014 Feb 1;134(3):703-16.
-
9. Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE: GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3, Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13
-
10. Schmidt R, Faldum A, Witt O, Gerss J. Adaptive designs with arbitrary dependence structure. Biom J. 2014 Jan;56(1):86-106.
2013
-
1. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, Radlwimmer B, Højfeldt JW, Truffaux N, Castel D, Schubert S, Ryzhova M, Seker-Cin H, Gronych J, Johann PD, Stark S, Meyer J, Milde T, Schuhmann M, Ebinger M, Monoranu CM, Ponnuswami A, Chen S, Jones C, Witt O, Collins VP, von Deimling A, Jabado N, Puget S, Grill J, Helin K, Korshunov A, Lichter P, Monje M, Plass C, Cho YJ, Pfister SM. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2015 May 11;27(5):728-43.
-
2. Oehme I, Lodrini M, Brady NR and Witt O: Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas. Autophagy, Vol. 9, Issue 12, 2013.
-
3. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 2013 Aug 1;122(5):684-93.
-
4. Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S, Hielscher T, Pfister SM, Witt O, Rommelaere J, Schlehofer JR, Witt H: Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer. 2013 Jul 13. doi: 10.1002/ijc.28386. [Epub ahead of print]
-
5. Ecker J, Witt O, Milde T. Targeting of histone deacetylases in brain tumors, CNS Oncol. 2013 Jul;2(4):359-76. doi: 10.2217/cns.13.24. PMID: 25054580 [PubMed - in process]
-
6. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM; International Cancer Genome Consortium PedBrain Tumor Project: Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
-
7. Oehme I, Linke JP, Böck BC, Milde T, Lodrini M, Hartenstein B, Wiegand I, Eckert C, Roth W, Kool M, Kaden S, Gröne HJ, Schulte JH, Lindner S, Hamacher-Brady A, Brady NR, Deubzer HE, Witt O: Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):E2592-601. doi: 10.1073/pnas.1300113110. Epub 2013 Jun 25.
-
8. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M: Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell. 2013 Jul 8;24(1):75-89. doi: 10.1016/j.ccr.2013.05.005. Epub 2013 Jun 20.
-
9. Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, Schulte JH, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler MU, Kulozik AE, Westermann F, Witt O, Deubzer HE: MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res. 2013 Jul;41(12):6018-33. doi: 10.1093/nar/gkt346. Epub 2013 Apr 26.
-
10. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan 12;381(9861):116.
2012
-
1. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012 Oct 16;22(4):425-37. doi: 10.1016/j.ccr.2012.08.024.
-
2. Combs SE, Kessel KA, Herfarth K, Jensen A, Oertel S, Blattmann C, Ecker S, Hoess A, Martin E, Witt O, Jäkel O, Kulozik AE, Debus J: Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. Radiat Oncol. 2012 Oct 17;7:170. doi: 10.1186/1748-717X-7-170.
-
3. Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, Antunes AS, Oehme I, Pekrun A, Pfister SM, Kulozik AE, Witt O, Deubzer HE: HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J Neurooncol. 2012 Dec;110(3):335-48. doi: 10.1007/s11060-012-0978-1. Epub 2012 Oct 6.
-
4. Deubzer HE, Schier MC, Oehme I, Lodrini M, Haendler B, Sommer A, Witt O: HDAC11 is a novel drug target in carcinomas. Int J Cancer. 2013 May 1;132(9):2200-8. doi: 10.1002/ijc.27876. Epub 2012 Oct 25.
-
5. Witt O, Milde T, Deubzer HE, Oehme I, Witt R, Kulozik A, Eisenmenger A, Abel U, Karapanagiotou-Schenkel I: Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr. 2012 Oct;224(6):398-403. doi: 10.1055/s-0032-1323692. Epub 2012 Aug 22.
-
6. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Tonini GP, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Collins VP, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P: Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 2;488(7409):100-5. doi: 10.1038/nature11284.
-
7. Dovzhanskiy DI, Arnold SM, Hackert T, Oehme I, Witt O, Felix K, Giese N, Werner J. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer. 2012 Jun 8;12(1):226.
-
8. Milde T, Hielscher T, Witt H, Kool M, Mack SC, Deubzer HE, Oehme I, Lodrini M, Benner A, Taylor MD, von Deimling A, Kulozik AE, Pfister SM, Witt O, Korshunov A: Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol. 2012 Nov;22(6):848-60. doi: 10.1111/j.1750-3639.2012.00600.x. Epub 2012 May 30.
-
9. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Jan 29;482(7384):226-31. doi: 10.1038/nature10833. Erratum in: Nature. 2012 Apr 5;484(7392):130.
-
10. Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO: Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012 Jan 20;148(1-2):59-71. doi: 10.1016/j.cell.2011.12.013.
-
11. Jones DT, Gronych J, Lichter P, Witt O, Pfister SM: MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci. 2012 Jun;69(11):1799-811. doi: 10.1007/s00018-011-0898-9. Epub 2011 Dec 13. Review.
-
12. Bai AH, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, Kool M, Northcott PA, Jugold M, Bazhin AV, Eichmüller SB, Kulozik AE, Pscherer A, Benner A, Taylor MD, Pomeroy SL, Kemkemer R, Witt O, Korshunov A, Lichter P, Pfister SM: MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012 Apr;123(4):529-38. doi: 10.1007/s00401-011-0924-x. Epub 2011 Dec 2.
2011
-
1. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P, Kopp HG, Jugold M, Deubzer HE, Oehme I, Lodrini M, Gröne HJ, Benner A, Brüstle O, Gilbertson RJ, von Deimling A, Kulozik AE, Pfister SM, Martin-Villalba A, Witt O: A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol. 2011 Aug 24. [Epub ahead of print]
-
2. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, Wittmann A, Yao Y, Roberts SS, Massimi L, Van Meter T, Weiss WA, Gupta N, Grajkowska W, Lach B, Cho YJ, von Deimling A, Kulozik AE, Witt O, Bader GD, Hawkins CE, Tabori U, Guha A, Rutka JT, Lichter P, Korshunov A, Taylor MD, Pfister SM: Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011 Aug 16;20(2):143-57.
-
3. Jacob K, Khuong Quang DA, Jones DT, Witt H, Lambert SR, Albrecht S, Witt O, Vezina C, Shirinian M, Faury D, Garami M, Hauser P, Klekner A, Bognar L, Farmer JP, Montes JL, Atkinson J, Korshunov A, Hawkins CE, Collins VP, Pfister SM, Tabori U, Jabado N: Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res. 2011 May 24. [Epub ahead of print]
-
4. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister SM: Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011 Jun;121(6):763-74. Epub 2011 Mar 20.
-
5. Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D, Remke M, Hartmann C, Witt H, Jones DT, Witt O, Heiland S, Bendszus M, Holland EC, Pfister S, Lichter P: An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest. 2011 Apr 1;121(4):1344-8. doi: 10.1172/JCI44656. Epub 2011 Mar 14.
-
6. Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, Kulozik AE, Wick W, Debus J, Combs SE: Outcome and Prognostic Factors of Radiation Therapy for Medulloblastoma. Int J Radiat Oncol Biol Phys. 2011 Feb 22. [Epub ahead of print]
-
7. Ley S, Ley-Zaporozhan J, Günther P, Deubzer HE, Witt O, Schenk JP: Neuroblastoma imaging. Rofo. 2011 Mar;183(3):217-25. Epub 2010 Dec 17. Review.
2010
-
1. Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM: TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol. 2010 Dec 10;28(35):5188-96. Epub 2010 Nov 8.
-
2. Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs SE: Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept. BMC Cancer. 2010 Aug 23;10:450.
-
3. Böck BC, Tagscherer KE, Fassl A, Krämer A, Oehme I, Zentgraf HW, Keith M, Roth W: The PEA-15 protein regulates autophagy via activation of JNK. J Biol Chem. 2010 Jul 9;285(28):21644-54. Epub 2010 May 7.
-
4. Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, Weber KJ: Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):237-45. Epub 2010 Jun 18.
-
5. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schöttler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S: Molecular Staging of Intracranial Ependymoma in Children and Adults. J Clin Oncol. 2010 Jun 1. [Epub ahead of print]
-
6. Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S, Wolff JE: Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma. J Pediatr Hematol Oncol. 2010 May 11. [Epub ahead of print]
-
7. Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott PA, Deubzer HE, Lodrini M, Taylor MD, von Deimling A, Pfister S, Witt O: Histone Deacetylases 5 and 9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clin Cancer Res. 2010 Apr 22. [Epub ahead of print]
-
8. Korshunov A, Remke M, Gessi M, Ryzhova M, Hielscher T, Witt H, Tobias V, Buccoliero AM, Sardi I, Gardiman MP, Bonnin J, Scheithauer B, Kulozik AE, Witt O, Mork S, von Deimling A, Wiestler OD, Giangaspero F, Rosenblum M, Pietsch T, Lichter P, Pfister SM: Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010 Apr 21. [Epub ahead of print]
-
9. Lacroix J, Leuchs B, Li J, Hristov G, Deubzer HE, Kulozik AE, Rommelaere J, Schlehofer JR, Witt O: Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer. 2010 Jan 19. [Epub ahead of print]
2009
-
1. Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O: Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs. 2009 Sep 28. [Epub ahead of print]
-
2. Witt O, Hämmerling S, Stockklausner C, Schenk JP, Günther P, Behnisch W, Hamad B, Al Mulla NA, Kulozik A: 13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis. J Pediatr Hematol Oncol. 2009 Apr;31(4):296-9.
-
3. Pfister S, Witt O: Pediatric gliomas. Recent Results Cancer Res. 2009;171:67-81.
-
4. Witt O, Lindemann R: HDAC inhibitors: Magic bullets, dirty drugs or just another targeted therapy. Cancer Lett. 2009 Mar 18. [Epub ahead of print]
-
5. Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I: Targeting histone deacetylases in neuroblastoma. Curr Pharm Des. 2009;15(4):436-47.
-
6. Ecke I, Petry F, Rosenberger A, Tauber S, Mönkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA, Uhmann A, Nitzki F, Wojnowski L, Schulz-Schaeffer W, Witt O, Hahn H: Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009 Feb 1;69(3):887-95. Epub 2009 Jan 20.
-
7. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O: Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009 Jan 1;15(1):91-9.
-
8. Milde T, Pfister S, Korshunov A, Deubzer HE, Oehme I, Ernst A, Starzinski-Powitz A, Seitz A, Lichter P, von Deimling A, Witt O: Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes Cancer. 2009 Mar;48(3):229-38.
2008
-
1. Frühwald MC, Witt O (2008) The epigenetics of cancer in children. Klin Padiatr. 2008 Nov-Dec;220(6):333-41
-
2. Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J Jr. (2008) Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res. 2008 Oct 15;14(20):6531-7
-
3. Witt O, Deubzer HE, Milde T, Oehme I (2008) HDAC family: What are the cancer relevant targets? Cancer Lett. 2008 Sep 26. [Epub ahead of print]
-
4. Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O (2008) HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anticancer Drugs. 2008 Oct;19(9):849-57
-
5. Schulte JH, Kirfel J, Lim S, Schramm A, Friedrichs N, Deubzer HE, Witt O, Eggert A, Buettner R (2008) Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. Cancer Lett. 2008 Nov 18;271(1):56-63
-
6. Wegener D, Hildmann C, Riester D, Schober A, Meyer-Almes FJ, Deubzer HE, Oehme I, Witt O, Lang S, Jaensch M, Makarov V, Lange C, Busse B, Schwienhorst A (2008) Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay. Biochem J. 2008 Jul 1;413(1):143-50
-
7. Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, Riester D, Schwab M, Witt O (2008) Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett. 2008 Jun 8;264(1):21-8
-
8. Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, Schwab M, Witt O (2008) Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer. 2008 Apr 15;122(8):1891-900
Selected Publications 1996-2007
-
1. Graf von Einsiedel H, Kawan L, Eckert C, Fichtner I, Witt O, Seeger K, Henze G (2006) Histone Deacetylase Inhibitors have antitumor activity in two NOD/SCID-mouse models of B-cell precursor childhood acute lymphoblastic leukemia, Leukemia 20: 1435-1436
-
2. Deubzer H, Busche B, Rönndahl G, Eikel D, Michaelis M, Cinatl J, Schulze S, Nau H, Witt O (2006) Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukaemia cells, Leukemia Res. 30: 1167-1175
-
3. Rönndahl G, Mönkemeyer S, Schulze S, Pekrun A, Eikel D, Nau H, Witt O (2006) Novel valproic acid derivatives with haemoglobin F inducing activity, Am J Hematol. 81:374-376
-
4. Witt O, Schweigerer L, Hernaiz-Driever P, Wolff J, Pekrun A (2004). Valproic acid treatment of glioblastoma multiforme in a child, Pediatr Blood & Cancer 43:181
-
5. Witt O, Mönkemeyer S, Rönndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A (2003) Induction of fetal hemoglobin expression by the histone-deacetylase inhibitor apicidin, Blood 101:2001-2007
-
6. Witt O, Mönkemeyer S, Rönndahl G, Kanbach K, Pekrun A (2002) Induction of fetal hemoglobin synthesis by valproate: modulation of MAPkinase pathways, Am J Hematol. 71: 45-46
-
7. Witt O, Schulze S, Kanbach K, Roth C, Pekrun A (2001) Tumor cell differentiation by butyrate and environmental stress, Cancer Lett. 171: 173-182
-
8. Witt O, Sand K, Pekrun A (2000) Butyrate induced erythroid differentiation of human K562 cells involves inhibition of ERK and activation of p38 MAP kinase-pathways, Blood 95: 2391-2396
-
9. Witt O, Albig W, Doenecke D (1998) A cAMP responsive/phorbol ester element is involved in transcriptional regulation of the human replacement histone gene H3.3B, Biochem J 329: 609-613
-
10. Witt O, Albig W, Doenecke D (1997) Transcriptional regulation of the human replacement histone gene H3.3B, FEBS Lett. 408: 255-260
-
11. Witt O, Albig W, Doenecke D (1996) Testis-specific expression of a novel human H3 histone gene, Exp Cell Res. 229: 301-306
Book chapters
-
1. Hendrik Witt , Andrey Korshunov, Marc Remke, Stefan Pfister, Olaf Witt, Till Milde: Progressively metastasizing ependymoma: genomic aberrations. In: M.A. Hayat (ed.), Tumors of the Central Nervous System, 2012, Volume 8, Part 7, 297-306; Springer Verlag. DOI 10.1007/978-94-007-4213-0_29
-
1. Pfister S. and Witt O: Medulloblastoma. In: Encyclopedia of Molecular Mechanisms of Disease, Springer-Verlag, Heidelberg, in press
-
2. Witt O: Histone Deacetylases. In: Encyclopedia of Cancer (Ed. M. Schwab), 2nd ed., 2009, Springer-Verlag, Heidelberg
-
3. Witt O: Sirtuins. In: Encyclopedia of Cancer (Ed. M. Schwab), 2nd ed., 2009, Springer-Verlag, Heidelberg
Pending patent applications
- Deubzer HE, Ehemann V, Heinrich R, Rönndahl G, Westermann F, Witt O. Means and methods for treating advanced stage neuroblastoma. 23.12.2005: EP 05 028 301.9.
- Deubzer HE, Ehemann V, Becker G, Westermann V, Schwab M, Witt O. Histone deacetylase inhibitor Helminthosporium carbonum toxin for suppressing malignant qualities of neuroblastoma cells. 20.10.2006: US 60/853,022.
- Deubzer HE, Ehemann V, Heinrich R, Rönndahl G, Westermann F, Witt O. Means and methods for treating advanced stage neuroblastoma. 22.12.2006: PCT/EP2006/069776.
- Deubzer HE and Witt O. Methods for treating and preventing brain tumors based on bone morphogenetic proteins. 13.2.2008 US 61/028,731
- Brady, Witt, Oehme. Histone Deacetylase 10-inhibitor Co-Treatment in Cancer.4.7.2013: PCT/EP2012/075942
- Rommelaere, Lacroix, Schlehofer, Witt, Deubzer, Kern, Herold-Mende, Geletneky, Leuchs. Use of parvovirus to eliminate cancer stem cells (CSCs). 15.8.2013: US 2013/0209413A1
Press Releases
-
Press Release of october 13th, 2014: Hector award oncology 2014 to Ina Oehme, on "dkfz.de" (in German only)
-
Press Release of october 14th, 2014: Hector award oncology 2014 to Ina Oehme, on "morgenweb.de" ("Mannheimer Morgen") (in German only)
-
Press Release of June 2nd, 2014: Kind Philipp award to Dr. Ina Oehme and Dr. David Jones, on "kinderkrebsinfo.de" (in German only)
-
Press Release of June 2nd, 2014: Kind Philipp award to Dr. Ina Oehme and Dr. David Jones, on "dkfz.de" (in German only)
-
Press Release of May 23rd, 2014: Kind Philipp award to Dr. Ina Oehme and Dr. David Jones, on "Deutsches Stiftungszentrum" (in German only)
-
Press Release of August 1st, 2013: Histone deacetylase 10 (HDAC10), on "SciBX"
-
Press Release of July 1st, 2013: Neuroblastoma: Autophagy Protects From Chemotherapy
-
Press Release of October 29th, 2009: Targeted treatment of pediatric neural cancer, on "Informationsdienst Wissenschaft" (in German only)
-
Press Release of January 8th, 2009: Anticancer drugs targeting HDAC8 (in German only)
-
Press Release of January 16th, 2008: Plant Pathogen Yields Substance to Fight Neuroblastoma
to top
